Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
natural product
macrolide lactone |
| gptkbp:ATCCode |
none
|
| gptkbp:canBe |
anticancer agent
Alzheimer's disease therapy HIV latency reversal |
| gptkbp:CASNumber |
83314-01-6
|
| gptkbp:category |
metabolite
marine natural product |
| gptkbp:chemicalFormula |
C47H68O17
|
| gptkbp:clinicalTrialPhase |
Phase II
|
| gptkbp:discoveredIn |
1970s
|
| gptkbp:firstIsolatedFrom |
gptkb:Bugula_neritina
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bryostatin 1
|
| gptkbp:IUPACName |
(1R,3S,5Z,7R,8E,11S,12S,13E,15S,17R,20R,23R,25S,27R,28S)-1,20,27-trihydroxy-17-[(1R)-1-hydroxyethyl]-5,13,19,25-octamethyl-11,15,23,28-tetraoxabicyclo[23.3.1]octacosa-3,5,7,8,13,15,19-heptaene-12,25-diyl diacetate
|
| gptkbp:mechanismOfAction |
protein kinase C modulator
|
| gptkbp:molecularWeight |
905.03 g/mol
|
| gptkbp:origin |
marine bryozoan
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL375324
5280752 |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting fatigue myalgia |
| gptkbp:solubility |
poorly soluble in water
soluble in DMSO |
| gptkbp:UNII |
1D1Q1V6X2M
|
| gptkbp:bfsParent |
gptkb:bryostatin-1
|
| gptkbp:bfsLayer |
7
|